Nav: Home

Introduction of screening could significantly reduce lung cancer deaths

July 28, 2016

The introduction of lung cancer screening in the UK could significantly reduce deaths in high risk groups, without causing participants the undue stress sometimes associated with medical tests.

Published today in Thorax, a trial led by Cardiff University looked at long-term psychosocial outcomes of CT screening for lung cancer and found that it did not cause unnecessary anxiety, even though fear and stigma can sometimes be barriers to participation in screening.

Lung cancer is the leading cause of cancer-related mortality in the UK, killing almost 40,000 people per year. Additionally, around three quarters of patients are diagnosed at a late stage when fewer treatment options are available. With early detection of lung cancer about seven out of ten patients survive for a year or more.

Dr Kate Brain from Cardiff University said:

"With the UK's 5-year survival rate for lung cancer being lower than many other countries with comparable healthcare systems, it is important that we do more to introduce early detection strategies that help to ensure treatment is delivered before patients present at an advanced stage of the disease.

"Sometimes, fear of medical procedures and the results they might bring can prevent people from seeking life-saving tests. However, what our trial shows is that CT lung cancer screening actually has no long-term negative psychosocial impact on patients, making it an excellent tool for catching lung cancer earlier when there is a better chance of survival."

The UK Lung cancer screening trial (UKLS) recruited over 4,000 men and women, aged 50-75, at high risk of lung cancer. This group was randomised into two groups: one of which received a CT screen and one that didn't. Participants in both groups were assessed two weeks into the study and again two years later. To assess people's emotional responses to CT lung screening, standard measures of lung cancer distress, anxiety, depression and satisfaction were used. The research showed that lung cancer screening did not cause undue worry when people were followed up over the two year period. Participants who needed to have a repeat scan reported slightly higher cancer distress, but this was temporary. The results revealed that at both points more participants from the group that didn't receive scans were dissatisfied with their decision to take part in the trial. It also found, regardless of group allocation, cancer distress was higher in women, participants under 65, current smokers and those with lung cancer experience.

The trial was undertaken in Liverpool and Papworth, whilst the in-depth analysis of the psychosocial data was carried out in Cardiff. The evidence produced will contribute to clinical and policy decisions regarding the successful and equitable implementation of potential future low-dose CT lung screening for high-risk individuals.
-end-
Institutions involved in the study include Cardiff University, Liverpool University, Royal Brompton & Harefield NHS Foundation Trust, Nottingham University Hospitals and Queen Mary University of London.

The trial 'Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomized controlled trial' is published in Thorax. Funder: NIHR Health Technology Assessment programme.

Notes for editors

Cardiff University is recognised in independent government assessments as one of Britain's leading teaching and research universities and is a member of the Russell Group of the UK's most research intensive universities. The 2014 Research Excellence Framework ranked the University 5th in the UK for research excellence. Among its academic staff are two Nobel Laureates, including the winner of the 2007 Nobel Prize for Medicine, University Chancellor Professor Sir Martin Evans. Founded by Royal Charter in 1883, today the University combines impressive modern facilities and a dynamic approach to teaching and research. The University's breadth of expertise encompasses: the College of Arts, Humanities and Social Sciences; the College of Biomedical and Life Sciences; and the College of Physical Sciences and Engineering, along with a longstanding commitment to lifelong learning

Cardiff University

Related Lung Cancer Articles:

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.
Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.
Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.
Better equipped in the fight against lung cancer
Lung cancer is the third most common type of cancer in Germany and the disease affects both men and women.
New liquid biopsy-based cancer model reveals data on deadly lung cancer
Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes.
Cancer drug leads to 'drastic decrease' in HIV infection in lung cancer patient
Doctors in France have found the first evidence that a cancer drug may be able to eradicate HIV-infected cells in humans.
Air pollution is associated with cancer mortality beyond lung cancer
A large scale epidemiological study associates some air pollutants with kidney, bladder and colorectal cancer death.
More Lung Cancer News and Lung Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.